ELUVIA™

Drug-Eluting Vascular Stent System

Restenosis in the SFA

A harsh SFA environment
Significant mechanical forces in the SFA prolong the response to injury and make the SFA susceptible to restenosis.
Clinical History of Restenosis
Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611–617.

 

Restenosis following nitinol stenting peaks at about 12 months in the SFA.

SUSTEND™ Drug-Delivery Technology

The Eluvia™ Stent, with Sustend™ drug-delivery technology, is designed to deliver paclitaxel when restenosis is most likely to occur.

Polymer-based technology with proven biocompatibility

  •  Implanted in more than 10 million vessels since 20071
  •  More than 20,000 patients studied in clinical trials2
DRUG TISSUE CONCENTRATIONS OVER TIME
*Based on pre-clinical PK analysis. Data on file at Boston Scientific.
Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.

 

More than 12 months of sustained drug release

Built on the Innova™ Stent platform, designed to provide uniform scaffolding for drug delivery while optimizing:

  •  Flexibility
  •  Radial strength
  •  Fracture resistance
Product Overview

Product Overview

Advanced drug-eluting technology for PAD.

Button
Clinical Programs

Clinical Programs

Unprecedented clinical data outcomes in the SFA.

Button
Product Design

Product Design

Built on the proven InnovaTM Stent platform.

Button
Top